

# Gene Set Analyses using Bayesian MAGMA Models


Peter Sørensen

# From GWAS to Biological Discovery

BLR Adjusted  
GWAS summary statistics

Link genetic markers to  
information in biological  
databases

Functional marker sets  
enriched for disease  
association



*“Utilising cleaner and stronger marker signals linked to functional marker information and jointly analysing multiple functional marker sets and diseases may help better understand disease biology and subsequently be used to identify novel drug targets.”*

# Gene Set Analysis

**Gene set analysis** evaluates the **coordinated action of genes or sets of variants** within predefined biological pathways or functional groups.

**GWAS** identify single genetic variants (SNPs) associated with traits or diseases.

- **Many variants have small individual effects**  
→ Use larger datasets or make better use of existing data.
- **Some effects are clustered within functionally related genes or pathways**  
→ Use prior information on functional marker groups to improve detection power and interpretation.
- **Some effects are shared across multiple traits**  
→ Leverage correlated trait information to enhance detection power and prediction accuracy.

# Gene Set Analyses

Many different gene set analysis approaches have been proposed.

- **MAGMA**: Multi-marker Analysis of GenoMic Annotation (Leuww et al 2015)
  - generalized gene set analysis of GWAS data
  - based on a multiple regression model
  - rank gene sets
- **PoPS**: Polygenic Prioritisation Scoring (Weeks et al 2023)
  - leveraging polygenic enrichment of gene features (e.g. gene sets) to predict genes underlying complex diseases
  - based on a multiple regression model
  - rank genes

# MAGMA: Linear Model Approach

**MAGMA** fits a **linear regression model** to test associations between **gene sets** and traits.

1. Aggregate **SNP-level GWAS statistics** into **gene-level statistics**, accounting for LD.
2. Use gene-level statistics as the **response variable**.
3. Represent gene sets as a **predictor matrix**, typically indicating gene membership, but not necessarily limited to binary values.
4. Estimate regression coefficients to assess the **strength of association** between each gene set and the trait.
5. Evaluate significance using **permutation** or **model-based null distributions**.

## MAGMA: Limitations

When analyzing thousands of gene sets, several issues arise:

- **Overfitting** – the model may capture noise rather than true signals.
- **Multicollinearity** – many gene sets are correlated due to biological overlap.
- **Multiple testing** – increases false-positive risk.
- **Interpretation difficulty** – hard to disentangle contributions of overlapping sets.

→ Use of **regularization** and **variable selection** to improve model robustness and interpretability.

Additionally, many complex traits are **genetically correlated**, sharing overlapping biological pathways.

→ Incorporating **multi-trait information** in MAGMA can increase detection power and reveal shared genetic mechanisms across traits.

# Bayesian MAGMA: Idea

Develop and evaluate a **Bayesian gene-set prioritization approach** using BLR within the MAGMA framework.

- Advantages:
  - Incorporates **regularization** and **variable selection** via **spike-and-slab priors**.
  - Controls false positives and **handles overlapping gene sets**.
  - Provides **posterior inclusion probabilities (PIP)** as evidence of gene set association.
- Flexible framework supporting:
  - **Single- and multi-trait models**
  - **Integration of diverse genomic features**
  - **Modeling of correlated traits** to uncover shared genetic factors.

## Bayesian MAGMA: Regression Model

The **Bayesian MAGMA** framework builds on the standard regression model:

$$\mathbf{Y} = \mathbf{X}\beta + \varepsilon, \quad \varepsilon \sim \mathcal{N}(0, \sigma^2 \mathbf{I})$$

- $\mathbf{Y}$  — vector of **observed outcomes** or **gene-/set-level association measures**
- $\mathbf{X}$  — matrix of **genomic predictors** (e.g., gene membership, functional annotations, or pathway indicators)
- $\beta$  — vector of **effect sizes** describing how predictors in  $\mathbf{X}$  explain variation in  $\mathbf{Y}$
- $\varepsilon$  — **residual noise** capturing unexplained variation

In the **Bayesian formulation**, each  $\beta_j$  is assigned a **prior distribution** that encodes assumptions about **effect size magnitude, sparsity, or functional grouping**.

These priors enable **regularization, variable selection, and information sharing** across correlated features or biological layers.



# Bayesian MAGMA: Multivariate Motivation

- Traditional single-trait analyses may miss associations that are **weak individually but consistent across traits**.
- **Multi-trait Bayesian MAGMA** leverages these correlations by jointly modeling multiple traits to:
  - Increase **power** for detecting gene sets and pathways,
  - Improve **accuracy** of effect estimation, and
  - Reveal **shared biological mechanisms** underlying complex diseases.

# Bayesian MAGMA: Multivariate Regression Model

In the **multivariate BLR** model, we model **multiple correlated outcomes** jointly:

$$\mathbf{Y} = \mathbf{XB} + \mathbf{E}$$

- $\mathbf{Y}$ :  $(n \times T)$  matrix of outcomes  
(e.g., association measures for  $T$  traits or omic layers)
- $\mathbf{X}$ :  $(n \times p)$  feature matrix
- $\mathbf{B}$ :  $(p \times T)$  matrix of effect sizes
- $\mathbf{E}$ :  $(n \times T)$  residual matrix

Each row of  $\mathbf{Y}$  corresponds to an observation or gene, and each column to a trait, phenotype, or molecular layer.

# Bayesian MAGMA: Error and Effect Priors

We extend the univariate priors to the multivariate setting:

$$\mathbf{e}_{i.} \sim \mathcal{N}_T(\mathbf{0}, \Sigma_e)$$

$$\mathbf{b}_{j.} \sim \mathcal{N}_T(\mathbf{0}, \Sigma_b)$$

- $\Sigma_e$ : residual covariance among traits ( $\mathbf{e}_{i.}$  is the vector of **residuals** for observation  $i$  across all  $T$  traits)
- $\Sigma_b$ : covariance of effect sizes across traits ( $\mathbf{b}_{j.}$  is the vector of **effect sizes** for feature  $j$  across all  $T$  traits)

When the **off-diagonal elements are nonzero**, the model **borrows information across correlated traits**, enabling detection of **pleiotropic effects** and **shared genetic factors**.

When  $\Sigma_e$  and  $\Sigma_b$  are diagonal, the model reduces to  $T$  independent univariate BLR models.

# Bayesian MAGMA: Estimation of Effects

## Ordinary multiple regression

$$\mathbf{b} = (\mathbf{X}'\mathbf{X})^{-1}\mathbf{X}'\mathbf{y}$$

## With regularization

$$\mathbf{b} = \left( \mathbf{X}'\mathbf{X} + \mathbf{I} \frac{\sigma_e^2}{\sigma_b^2} \right)^{-1} \mathbf{X}'\mathbf{y}$$

## Using information from multiple responses

$$\mathbf{b} = (\mathbf{X}'\mathbf{X} + \mathbf{I} \otimes \Sigma_B^{-1} \Sigma_E)^{-1} \mathbf{X}'\mathbf{y}$$

## Bayesian MAGMA: Indicator Variables

Each feature  $j$  may affect multiple outcomes (traits).

We define an indicator vector for **cross-trait activity patterns**:

$$\delta_j = \begin{bmatrix} \delta_{j1} \\ \delta_{j2} \\ \vdots \\ \delta_{jT} \end{bmatrix}, \quad \delta_{jt} = \begin{cases} 1, & \text{if feature } j \text{ affects trait } t, \\ 0, & \text{otherwise.} \end{cases}$$

After Gibbs sampling, the **posterior inclusion probability (PIP)** is estimated as:

$$\widehat{\text{PIP}}_{jt} = \frac{1}{M} \sum_{m=1}^M \mathbb{I}(\delta_{jt}^{(m)} = 1) \approx P(\delta_{jt} = 1 \mid \text{data}),$$

representing the probability that feature  $j$  is associated with trait  $t$ .

# Bayesian MAGMA: Posterior Parameters

In the multivariate setting, we generalize each posterior quantity:

Parameter	Interpretation
$\mathbf{B} = [\beta_{jt}]$	Effect matrix across traits ( $j$ : feature, $t$ : trait)
$\mathbf{PIP} = [\text{PIP}_{jt}]$	Posterior inclusion probability matrix ( $j$ : feature, $t$ : trait)
$\Sigma_b$	Covariance of effects across traits
$\Sigma_e$	Residual covariance among traits

These posterior quantities allow us to identify:

- **Shared genetic effects** (pleiotropy)
- **Trait-specific vs. shared signals**
- **Cross-trait enrichment** of biological or functional sets

# Bayesian MAGMA. Study Aim and Design

Evaluate a **Bayesian gene-set prioritization approach** using BLR within the MAGMA framework.

## **Simulation study:**

- Assessed model performance under varying gene set characteristics and genetic architectures.
- Used **UK Biobank genetic data** for realistic evaluation.


## **Comparative analysis:**

- Benchmarked Bayesian MAGMA against the standard MAGMA approach.

## **Applications:**

- Applied to **nine complex traits** using publicly available GWAS data.
- Developed a **multi-trait BLR model** to integrate GWAS results across traits and uncover shared genetic architecture.

# Bayesian MAGMA: Overview




- Fits a Bayesian regression model that allows **regularization** and **variable selection**
- Supports **single- or multi-trait** analyses
- Identifies associated features based on **posterior inclusion probabilities** (PIPs) for the regression effects

Gholipourshahraki et al., 2024



# Bayesian MAGMA: Gene-level Statistics



Compute gene-level (or other feature-level) association statistics:

- Account for correlation among marker statistics (i.e., linkage disequilibrium, LD)
- Different LD-adjustment methods (e.g., SVD, clumping and thresholding, BLR)
- The choice of method depends on the quality of the available GWAS summary statistics and LD reference panel

# Bayesian MAGMA – KEGG Pathway

- GWAS summary statistics from nine studies (**T2D, CAD, CKD, HTN, BMI, WHR, Hb1Ac, TG, SBP**)
- **Gene sets** are defined by genes linked to **KEGG pathways**.
- Pathways relevant to **diabetes** are associated with **Type 2 Diabetes (T2D)** and correlated traits
- Enables identification of **cross-disease patterns** to better understand **comorbidities**

Gholipourshahraki et al., 2024

# Bayesian MAGMA – DGldb

- **Gene sets** are defined by genes linked to the **Anatomical Therapeutic Chemical (ATC)** classification system using the **Drug–Gene Interaction Database (DGldb)**
- **Drug gene sets relevant to diabetes** show associations with **Type 2 Diabetes (T2D)** and related traits
- **Novel drug–gene set associations** may reveal opportunities for **drug repurposing**

Hjelholt et al., 2025

# Bayesian MAGMA – Across Ancestries

- **Gene sets** are defined by genes linked to **KEGG pathways**.
- Joint analysis of **T2D** across three ancestries (**EUR**, **EAS**, **SAS**).
- Pathways relevant to **diabetes** show associations with **Type 2 Diabetes (T2D)** across two of the ancestries (**EUR** and **EAS**).
- Comparing these associations helps reveal **ancestry-specific biological mechanisms**.

# Summary

## Advantages

- Incorporates **regularization** and **variable selection** via *spike-and-slab* priors
- Accounts for **correlated gene sets and traits**, increasing power and reducing false positives
- Provides **posterior inclusion probabilities (PIPs)** as interpretable measures of association strength
- Flexible framework supporting:
  - **Single- and multi-trait models**
  - **Integration of diverse genomic features**
  - **Modeling of correlated traits** to uncover shared genetic architecture

## Limitations

- Dependent on the **quality and resolution** of GWAS summary statistics
- Sensitive to **biases and incompleteness** in functional annotations (e.g., tissue specificity, experimental noise, or overrepresentation of well-studied genes)
- **Computationally more demanding** than standard MAGMA, especially for multi-trait analyses

## Future Work

- Offers opportunities for **hierarchical model extensions** (e.g., grouping by genomic or functional layers)
- **Multi-omics integration** to capture regulatory complexity across biological layers
- Systematic **comparisons with machine learning and deep learning** methods to evaluate performance and scalability

## References

**Sørensen P, Rohde PD.** *A Versatile Data Repository for GWAS Summary Statistics-Based Downstream Genomic Analysis of Human Complex Traits.*

**medRxiv** (2025). <https://doi.org/10.1101/2025.10.01.25337099>

**Sørensen IF, Sørensen P.** *Privacy-Preserving Multivariate Bayesian Regression Models for Overcoming Data Sharing Barriers in Health and Genomics.*

**medRxiv** (2025). <https://doi.org/10.1101/2025.07.30.25332448>

**Hjelholt AJ, Gholipourshahraki T, Bai Z, Shrestha M, Kjølby M, Sørensen P, Rohde P.** *Leveraging Genetic Correlations to Prioritize Drug Groups for Repurposing in Type 2 Diabetes.*

**medRxiv** (2025). <https://doi.org/10.1101/2025.06.13.25329590>

**Gholipourshahraki T, Bai Z, Shrestha M, Hjelholt A, Rohde P, Fuglsang MK, Sørensen P.** *Evaluation of Bayesian Linear Regression Models for Gene Set Prioritization in Complex Diseases.* **PLOS Genetics** 20(11): e1011463 (2025).

<https://doi.org/10.1371/journal.pgen.1011463>

## Overview of BLR Models used in Gene Set Analyses

Model Type	Feature Integration	Grouping Basis	Prior Structure	What It Captures
<b>Single-component BLR</b>	Combines all biological features in one model	None	One global variance ( $\tau^2$ )	All features contribute equally; uniform shrinkage
<b>Multiple-component BLR</b>	Integrates all layers but allows heterogeneous contributions	Learned from data	Mixture of variances ( $\{\tau_k^2\}$ )	Large, small, and null effect classes
<b>Hierarchical BLR</b>	Groups features by biological structure (e.g., genes, pathways)	Defined <i>a priori</i>	Group-specific <b>mixture of variances</b> ( $\{\tau_{gk}^2\}$ )	Within-group heterogeneity; enrichment and



## Learning at Different Levels

Model Level	Key Parameters Learned	What They Represent	How They Are Learned	What We Learn Biologically
Effect sizes	$\beta$	Strength and direction of association for each feature	Posterior mean/median given priors and data	Which features drive the outcome
Indicator variables	$\delta_j$ (single trait), $\delta_j$ (multi-trait)	Whether feature $j$ is active (and for which traits)	Estimated as posterior inclusion probabilities (PIPs)	Which features are relevant, and whether effects are shared or trait-specific
Variance	$\tau^2, \{\tau_k^2\}, \{\tau_{\tau_k}^2\}$	Magnitude of expected	Inferred hierarchically	How strongly different